Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6KZMG)

Drug Name

Ozenoxacin Drug Info

Synonyms

T-3912; GF-001001-00; Non-fluorinated quinolone (Gram positive bacterial infection), Ferrer

Indication

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA replication (DNA repli)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[4]
Chlorambucil	DMRKE63	Chronic lymphocytic leukaemia	2A82.0	Approved	[5]
Elliptinium acetate	DMZC6GT	Solid tumour/cancer	2A00-2F9Z	Approved	[6]
DFP-10917	DM1WNGJ	Acute myeloid leukaemia	2A60	Phase 3	[7]
------------------------------------------------------------------------------------

Drug(s) Targeting Bacterial DNA gyrase (Bact gyrase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Grepafloxacin	DMGLX0T	Chronic bronchitis	CA20.1	Approved	[8]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[4]
Levofloxacin	DMS60RB	Acute maxillary sinusitis		Approved	[4]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[4]
Norfloxacin	DMIZ6W2	Acute gonococcal cervicitis		Approved	[4]
Sparfloxacin	DMB4HCT	Bacterial infection	1A00-1C4Z	Approved	[4]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[4]
Besifloxacin	DMPHXMI	Ocular inflammation	9C61.24	Approved	[9]
Finafloxacin	DMZEONG	Urinary tract infection	GC08	Approved	[10]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Staphylococcus Topoisomerase IV (Stap-coc parC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[4]
Levofloxacin	DMS60RB	Acute maxillary sinusitis		Approved	[4]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[4]
Sparfloxacin	DMB4HCT	Bacterial infection	1A00-1C4Z	Approved	[4]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[4]
Besifloxacin	DMPHXMI	Ocular inflammation	9C61.24	Approved	[9]
Finafloxacin	DMZEONG	Urinary tract infection	GC08	Approved	[10]
Delafloxacin Meglumine	DMVTU5Q	Acute bacterial skin infection	1C41	Approved	[1]
Moxifloxacin	DMU8V4S	Bacterial infection	1A00-1C4Z	Approved	[4]
Zabofloxacin	DMEY1F3	Pneumonia	CA40	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU; GYRB_STAAU	Modulator	[3]
DNA replication (DNA repli)	TTABD5E	NOUNIPROTAC	Inhibitor	[1]
Staphylococcus DNA gyrase A (Stap-coc gyrA)	TTRVWAT	GYRA_STAAU	Inhibitor	[1]
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Modulator	[3]

------------------------------------------------------------------------------------

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	ClinicalTrials.gov (NCT02090764) Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo. U.S. National Institutes of Health.
3	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23.
6	Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
9	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
10	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
11	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.